<![CDATA[<noframes id='50EE5BCF83'><address id='50EE5BCF83'></address>]]> <![CDATA[<code id='50EE5BCF83'></code><style id='50EE5BCF83'></style>]]>
<![CDATA[<acronym id='50EE5BCF83'></acronym>]]> <![CDATA[<center id='50EE5BCF83'><center id='50EE5BCF83'><tfoot id='50EE5BCF83'></tfoot></center><abbr id='50EE5BCF83'><dir id='50EE5BCF83'><tfoot id='50EE5BCF83'></tfoot><noframes id='50EE5BCF83'>]]>
<![CDATA[<optgroup id='50EE5BCF83'><strike id='50EE5BCF83'><sup id='50EE5BCF83'></sup></strike><code id='50EE5BCF83'></code></optgroup>]]>
<![CDATA[<style id='50EE5BCF83'><font id='50EE5BCF83'></font></style>]]>
<![CDATA[<b id='50EE5BCF83'><label id='50EE5BCF83'><select id='50EE5BCF83'><dt id='50EE5BCF83'><span id='50EE5BCF83'></span></dt></select></label></b><u id='50EE5BCF83'></u>]]> <![CDATA[<i id='50EE5BCF83'><strike id='50EE5BCF83'><tt id='50EE5BCF83'><small lang="78ce2c"></small><sup draggable="63b6c5"></sup><time dropzone="0c6a53"></time><pre date-time="9973cb" id='50EE5BCF83'></pre></tt></strike></i>]]>
Immix Biopharma (NASDAQ:IMMX) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis (NYSE:NVS) and Like: 7 Dislike: 995 
Leave a Comment